Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NTB 011

Drug Profile

NTB 011

Alternative Names: ABI-011; IDN 5404; IND-5404; nab-5404; nab-IND-5404; NTB-011

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abraxis BioScience; Indena
  • Developer Celgene Corporation
  • Class Antineoplastics; Colchicum alkaloids; Drug conjugates
  • Mechanism of Action Angiogenesis inhibitors; DNA topoisomerase I inhibitors; Tubulin polymerisation inhibitors; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Cancer in USA (IV)
  • 23 Aug 2019 NantBioScience withdraws a phase I trial for Solid tumours (Late-stage disease) and Lymphoma (Late-stage disease) prior to enrolment in USA as the enrolment was not initiated (IV) (NCT02582827)
  • 24 Oct 2015 NantBioScience plans a phase I trial for Solid tumours (Late-stage disease) and Lymphoma (Late-stage disease) in USA (IV) (NCT02582827)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top